Dr Min Quah has over 12 years of experience in the field of oncolytic immunotherapy. He was a key member in early discovery at Viralytics that was acquired for $502 million by Merck and Co in June 2018.
He is currently serving on ImmVirX’s management team leading the company’s clinical candidates operations including dose response, drug efficacy, and safety modelling in pre-clinical models.
Dr Quah holds a Doctorate in microbiology and immunology from the University of Newcastle, where he investigated the emerging role of oncolytic viruses in enhancing tumour immunotherapies. He is particularly interested in combining oncolytic viruses with current line of cancer therapies to achieve synergistic clinical benefits.
He holds a conjoint research fellow position with the University of Newcastle where he is passionate on inspiring next generation scientists.
